home / stock / zrsef / zrsef news
2024-03-21 17:25:10 ET DocMorris AG (ZRSEF) Q4 2023 Results Conference Call March 21, 2024 6:00 AM ET Company Participants Walter Hess - CEO Marcel Ziwica - CFO Conference Call Participants Sebastian Vogel - UBS Urs Kunz - Research Partners Milan ...
2024-03-21 10:22:22 ET More on DocMorris AG Historical earnings data for DocMorris AG Financial information for DocMorris AG Read the full article on Seeking Alpha For further details see: DocMorris AG reports FY results; initiates FY24 outlook
2023-08-17 11:58:25 ET More on DocMorris AG Earnings data for DocMorris AG For further details see: DocMorris AG GAAP EPS of 12.12, revenue of CHF462.9M
2023-03-24 01:45:29 ET The following slide deck was published by Zur Rose Group AG in conjunction with their 2022 Q4 earnings call. For further details see: Zur Rose Group AG 2022 Q4 - Results - Earnings Call Presentation
2023-03-24 01:12:06 ET 111, Inc. (YI) Q4 2022 Earnings Conference Call March 23, 2023 07:30 ET Company Participants Gang Yu - Co-Founder and Executive Chairman Junling Liu - Co-Founder, Chairman and Chief Executive Officer Luke Chen - Chief Financial Officer ...
2023-03-23 13:40:14 ET Zur Rose Group AG press release ( OTCPK:ZRSEF ): FY GAAP EPS of -CHF15.88. Revenue of CHF1.61B (-6.9% Y/Y). For further details see: Zur Rose Group AG GAAP EPS of -CHF15.88, revenue of CHF1.61B
Deutsche Bank boosted its rating on Zur Rose Group AG ( OTCPK:ZRSEF ) to a Hold rating after having the European pharmacy operator slotted at Hold. Sell rating from Hold. Analyst Jan Koch said following Zur Rose's ( OTCPK:ZRSEF ) surprising announcement to sell its Swiss business, the...